Thu Sep 19 06:12:04 UTC 2024: ## ™E Pharma’s CXCL12 Inhibitor NOX-A12 Shows Promise in Brain Tumor Treatment: Preclinical Data to be Presented at SNO Annual Meeting

**BERLIN, GERMANY – September 18, 2024** – ™E Pharma N.V., a clinical-stage biotechnology company focused on developing novel cancer therapies, announced today that preclinical data highlighting the efficacy of their CXCL12 inhibitor NOX-A12 in brain tumors will be presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting. The research was conducted at the U.S. National Cancer Institute (NCI) under a material transfer agreement established with ™E Pharma in June 2022.

The abstract, titled “Potentiating the efficacy of immune checkpoint inhibitors in glioblastoma by inhibition of CXCL12,” will be presented as a poster by Dr. Chen Cam-El Makranz, Neuro-Oncology Research Fellow at the NCI. The poster session will take place on Friday, November 22, 2024, from 7:30 p.m. to 9:30 p.m. CDT.

The research suggests that NOX-A12, by inhibiting CXCL12, a chemokine known to promote tumor growth and suppress immune responses, may enhance the effectiveness of immune checkpoint inhibitors in treating glioblastoma, an aggressive form of brain cancer.

™E Pharma will be present at the SNO Annual Meeting, the world’s largest neuro-oncology conference, as a supporting partner. Their team will be available for meetings with industry leaders.

This preclinical data adds to the growing body of evidence supporting the potential of NOX-A12 in treating brain tumors. ™E Pharma is currently conducting the GLORIA Phase 1/2 clinical trial evaluating NOX-A12 in newly diagnosed glioblastoma patients. The company has also received Fast Track designation from the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for the treatment of glioblastoma.

The full abstract will be published in the SNO official journal Neuro-Oncology on Friday, November 11, 2024. The abstract and poster presentation will be made available on the ™E Pharma website following the conference.

**About ™E Pharma**

™E Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers by targeting the tumor microenvironment. The company’s oncology-focused pipeline is designed to act on the tumor microenvironment and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair.

Read More